Satisfied With The Quality of Your Specialty Pharmacy Data?

Satisfied With The Quality of Your Specialty Pharmacy Data?

This may seem like a simple question, but when you consider the factors that impact data quality, it is quite complex.

 

Not unlike other businesses, pharma relies on a rich flow of data for making and assessing strategic decisions. For pharma, data comes from many different sources. The ability to capture patient data from multiple disparate sources, such as SP and HUB data, and integrate it with other types of patient information, including clinical lab results and claims data, can help pharmas with strategic planning and decision making. Inaccurate data is a root cause of over/understating sales, which can have a huge negative impact on strategic decision making and building performance measures.

 

Almost 400 drugs are currently delivered through SPs. Given the number of specialty drugs in the FDA queue, it’s estimated that up to 30 additional drugs could be approved by the FDA for SP distribution by the end of 2021.  For the existing companies with SP delivered drugs, now is a good time to evaluate the quality of the data delivered by your data integrator. If you are questioning why your Rx capture does not match your factory sales, you’ve got a problem. You’ve also got a problem if your Brand, Market Access, and Sales teams are debating the “numbers.” For emerging pharma companies expecting FDA approval and building commercialization plans in the next 12-18 months, the SP integrator you choose can significantly impact the quality of the data you use to make strategic decisions.

 

Integrating your SP network is only a part of the data capture. Accurately integrating SP and HUB data allows you to visualize part of the patient journey. In addition, data integrator-provided clinical lab results and other data can support your measuring and planning process. Quality data is driven by your integrator’s ability to help you see one patient as one patient, not as multiple patients.

 

Not all data integrators are equal. The concept of Anonymized Patient Level Data (APLD) may not seem complicated, but in essence, it is. In today’s data integrator marketplace there are simple, inexpensive solutions and a full-service solution. The saying goes: “You get what you pay for!” False positives and false negatives directly influence data quality, but how do you know you have an issue? With a simple solution, you are left figuring it out on your own.

 

With a simple solution you leverage technology for tokenization; without services, when the token chain breaks you are left with a data void that compromises your data quality.

 

The MSA full-service solution uses state-of-the-art technology supported by an extremely experienced service team of data scientists. MSA experts help ensure that tokenization and patient matching is accurate, based on the timely delivery of SP data and correctly populated fields. Industry-leading patient match rates enable MSA to make available the highest quality data.

 

Whether you are an emerging pharma company building pre-commercialization plans preparing to launch your first new brand or an established pharma with multiple SP-delivered brands, 2021 is the right time to evaluate your data capture/ quality and select MSA Healthcare Data Management (HCDM) as your integrator of choice.

 

As the market leader and integrator of choice to the Life Sciences industry, MSA HCDM offers pharma the most credentialed, most configurable, and most trusted HIPAA-compliant de-identification and matching solutions. The unparalleled service provided by MSA’s team of healthcare data management experts ensures the timely delivery of the highest quality data – the differentiating factor that many top life science companies rely on.

 

MSA’s structured methodology for integrating, protecting, and transforming disparate data from one or multiple sources into high-quality, longitudinally-aligned datasets leads to the actionable insights pharma requires to improve patient outcomes, reduce healthcare costs, and drive innovative research. MSA’s Data@Factory links de-identified, MSA-provided Lab, Medical Claims, and EHR Clinical Data with other disparate data from one or more sources, providing a longitudinal anonymous patient-level database for sophisticated data analytics of the comprehensive patient journey.

 

As the industry continues to expand and evolve, access to high quality SP data and information is more critical than ever. Connecting SP data to other data sources gives you the up-to 360 degree patient view necessary for strategic planning and decision making.

 

Learn more about MSA HCDM. Reach out to Frank Salopek, Director Business Development at fsalopek@msa.comVisit us at https://hcdm.msa.com.

 

Avatar
Frank Salopek
No Comments

Post a Comment

Comment
Name
Email
Website